WINDWARD BIO GROUP AG
Windward Bio Group AG develops ultra-long-acting antibody therapies for serious respiratory and dermatologic diseases. The company develops products for immunological conditions, including asthma, chronic obstructive pulmonary disease (COPD), and atopic dermatitis. The company develops WIN378, a fully human, ultra-long-acting monoclonal antibody targeting TSLP for severe uncontrolled asthma, moderate-to-severe COPD, chronic rhinosinusitis with nasal polyps, and eosinophilic esophagitis. It also develops WIN027, a humanized, ultra-long-acting bispecific monoclonal antibody targeting both TSLP and IL-13 for atopic dermatitis, COPD, chronic rhinosinusitis with nasal polyps, and asthma. Additionally, the company develops a bispecific antibody targeting T2 and non-T2 inflammatory pathways for atopic dermatitis, asthma, COPD, and other inflammatory and fibrotic skin and lung diseases. Windward Bio Group AG was incorporated in 2024 and is based in Basel, Switzerland.Windward Bio AG develops ultra-long-acting antibody medicines for patients with serious respiratory and dermatologic diseases, including asthma, chronic obstructive pulmonary disease (COPD), and atopic dermatitis. The company develops WIN378, a fully human, ultra-long-acting monoclonal antibody targeting thymic stromal lymphopoietin (TSLP) for the treatment of severe uncontrolled asthma and moderate-to-severe COPD, with potential additional indications in chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis, and other type-2-mediated allergic and inflammatory diseases. It also develops WIN027, a humanized, ultra-long-acting bispecific monoclonal antibody simultaneously targeting TSLP and interleukin-13 (IL-13) for the treatment of COPD and atopic dermatitis. It has operations in the United States. Windward Bio AG was incorporated in 2024 and is based in Basel, Switzerland.
No SEC Form 4 filings for $WWB in the last 30 days.
See all $WWB insider activity →Windward Bio Group (WWB) surged 40% after a $225M IPO and $50M private placement. LifeMD (LFMD) gained 30% on Q3 results and partnerships. SS Innovations (SSII) rose 20% with new leadership. Tandem Diabetes (TNDM) advanced 14% on FDA clearance for a tubeless insulin pump.
Windward Bio Group AG (WWB) priced its IPO at $17 per share, offering 10.3 million shares. It also secured a $50 million private placement from Sanofi, expecting $225 million in total proceeds. Shares will trade on Nasdaq starting Nov. 13, 2026, pending closing conditions. Joint book-runners include Jefferies, TD Cowen, Piper Sandler, and UBS.
Windward Bio Group AG, a Swiss drug developer, aims for a $1 billion valuation in its US IPO, selling 10.3 million shares at $16-$18 each. The company has raised $310 million from investors like Novo Holdings and is developing antibody medicines for respiratory and dermatologic diseases. Sanofi will purchase $50 million of shares. The IPO is underwritten by Jefferies, TD Cowen, Piper Sandler, and UBS, with a Nasdaq listing under 'WWB'.
Over the past 7 days, AlphAI's AI scored 6 news stories mentioning WWB (WINDWARD BIO GROUP AG). Coverage has skewed bullish: 5 bullish, 1 neutral, and 0 bearish.
Recent WWB coverage spans ipo and market movers.
Significant IPO pricing and capital raise.
Newly listed biotech likely sees initial buying interest and price volatility.
The IPO announcement provides fresh capital and market exposure, likely driving buying interest ahead of the offering.
New capital raise could provide funding for growth but dilutes existing shareholders.
AlphAI scores every news story that mentions WWB with an AI model for sentiment and relevance, and aggregates insider trades from WINDWARD BIO GROUP AG's SEC EDGAR Form 4 filings. Figures refresh continuously.
Windward Bio Group (WWB) surged 40% after a $225M IPO and $50M private placement. LifeMD (LFMD) gained 30% on Q3 results and partnerships. SS Innovations (SSII) rose 20% with new leadership. Tandem Diabetes (TNDM) advanced 14% on FDA clearance for a tubeless insulin pump.
Windward Bio Group AG (WWB) priced its IPO at $17 per share, offering 10.3 million shares. It also secured a $50 million private placement from Sanofi, expecting $225 million in total proceeds. Shares will trade on Nasdaq starting Nov. 13, 2026, pending closing conditions. Joint book-runners include Jefferies, TD Cowen, Piper Sandler, and UBS.
Windward Bio Group AG, a Swiss drug developer, aims for a $1 billion valuation in its US IPO, selling 10.3 million shares at $16-$18 each. The company has raised $310 million from investors like Novo Holdings and is developing antibody medicines for respiratory and dermatologic diseases. Sanofi will purchase $50 million of shares. The IPO is underwritten by Jefferies, TD Cowen, Piper Sandler, and UBS, with a Nasdaq listing under 'WWB'.
Windward Bio plans to raise up to $185M in a Nasdaq IPO, offering 10.3M shares at $16-$18 each. Sanofi will invest $50M in a private placement. Underwriters include Jefferies, TD Cowen, and others. The IPO is contingent on Nasdaq approval.
